Pan Guang-Dong, Wu Hong, Liu Jiang-Wen, Cheng Nan-Sheng, Xiong Xian-Ze, Li Sheng-Fu, Zhang Guo-Fu, Yan Lu-Nan
PO Box 119, West China Medical University, Chengdu 610041, Sichuan Province, China.
World J Gastroenterol. 2005 Oct 14;11(38):6061-5. doi: 10.3748/wjg.v11.i38.6061.
To investigate the effect of peroxisome proliferator-activated receptor gamma (PPAR-gamma) and its ligand, ciglitazone, on inflammatory regulation of human gallbladder epithelial cells (HGBECs) and to assess the effect of human epithelial growth factor (hEGF) on growth of HGBECs.
HGBECs were cultured in media containing hEGF or hEGF-free media. HGBECs were divided into normal control group, inflammatory control group and ciglitazone group (test group). Inflammatory control group and ciglitazone group were treated with 5 microg/L of human interleukin-1beta (hIL-1beta) to make inflammatory model of HGBECs. The ciglitazone group was treated with various concentrations of ciglitazone, a potent ligand of PPAR-gamma. Subsequently, interleukin-8 (IL-8), IL-6, and tumor necrosis factor-alpha (TNF-alpha) concentrations in all groups were measured. The data were analyzed statistically.
HGBECs were cultured in medium successfully. The longevity of HGBECs in groups containing hEGF was longer than that in hEGF-free groups. So was the number of HGBECs. The longest survival time of HGBEC was 25 d. The inflammatory model of HGBECs was obtained by treating with hIL-1beta. The concentrations of IL-6 and IL-8 in ciglitazone group were lower than those in inflammatory control group (P<0.05). The secretion of IL-6 in inflammatory control group was higher (350.31+/-37.05 microg/L) than that in normal control group (50.0+/-0.00 microg/L, P<0.001). Compared to normal control group, IL-8 concentration in inflammatory control was higher (P<0.05).
hEGF improves the growth of HGBECs in vitro. Ciglitazone inhibits the inflammation of HGBECs in vitro and has potential therapeutic effect on cholecystitis in vivo.
研究过氧化物酶体增殖物激活受体γ（PPAR-γ）及其配体吡格列酮对人胆囊上皮细胞（HGBECs）炎症调节的影响，并评估人表皮生长因子（hEGF）对HGBECs生长的作用。
将HGBECs培养于含hEGF的培养基或不含hEGF的培养基中。HGBECs分为正常对照组、炎症对照组和吡格列酮组（试验组）。炎症对照组和吡格列酮组用5μg/L的人白细胞介素-1β（hIL-1β）处理以建立HGBECs的炎症模型。吡格列酮组用不同浓度的吡格列酮（一种有效的PPAR-γ配体）处理。随后，测定所有组中白细胞介素-8（IL-8）、IL-6和肿瘤坏死因子-α（TNF-α）的浓度。对数据进行统计学分析。
HGBECs成功培养于培养基中。含hEGF组的HGBECs存活时间长于不含hEGF组，细胞数量也是如此。HGBECs最长存活时间为25天。用hIL-1β处理获得了HGBECs的炎症模型。吡格列酮组中IL-6和IL-8的浓度低于炎症对照组（P<0.05）。炎症对照组中IL-6的分泌量（350.31±37.05μg/L）高于正常对照组（50.0±0.00μg/L，P<0.001）。与正常对照组相比，炎症对照组中IL-8浓度更高（P<0.05）。
hEGF可促进体外HGBECs的生长。吡格列酮可抑制体外HGBECs的炎症反应，对体内胆囊炎具有潜在治疗作用。
